AllSci News
Bayer raises EUR 3.0 billion by selling minority stake in contraceptives unit
Bayer (ETR: BAYN) has secured €3.0 billion in equity capital from Apollo Global Management (NYSE: APO) through a minority stake in a newly established...
MindRank's USD 52m Series B advances AI-designed GLP-1 into pivotal Phase III obesity trial
China-based MindRank AI Ltd. has closed a USD 52 million Series B financing round to advance its AI-native drug discovery platform and clinical pipeline,...
Bausch + Lomb's glaucoma neuroprotective candidate fails Phase II primary endpoint
Bausch + Lomb's BL1107 glaucoma Phase II trial failed to replicate earlier visual function signals in primary open-angle glaucoma, a setback that closes the...
Apertura partners with NIH on TfR1 capsid approach for Niemann-Pick gene therapy
New York-based Apertura Gene Therapy has entered a Cooperative Research and Development Agreement with two NIH institutes to advance preclinical...
Roche discontinues huntingtin-targeting antisense programs tominersen and RG6496 in Huntington's disease
Roche has announced the discontinuation of two Huntington's disease programs simultaneously: the Phase II GENERATION HD2 study of tominersen (RG6042), a...
FDA pauses CRL publication while HHS develops formal disclosure rule
Category: Regulatory Policy | Regulatory Body: FDA | Geography: United States | Instrument: Rule/Rulemaking
JAX joins Broad-led consortium on USD 34.5 million ARPA-H rare disease gene-editing award
The Jackson Laboratory (JAX), in collaboration with the Broad Institute and partners across 12 institutions, has been selected for an up to USD 34.5 million...
Sparian Biosciences advances non-opioid pain drug toward clinical testing with NIDA support
Sparian Biosciences, a New York-based for-profit company, has received a USD 3.1 million NIDA UG3 grant to advance SBS-147, an oral non-opioid analgesic,...
JCVI receives USD 1.79 million NIAID grant to advance phage therapy toward FDA IND
J. Craig Venter Institute has received a USD 1.79 million NIAID R01 award to advance a five-phage therapeutic cocktail targeting antibiotic-resistant...
Cūrza backed by NIAID award for novel ribosomal inhibitor to combat multidrug-resistant infections
Curza Inc, a Salt Lake City-based antibiotic developer, has received a USD 1 million NIAID SBIR award to advance CZ-02, a novel class of oral antibiotics...
Sanford Burnham Prebys develops single-construct gene therapy to boost cardiac cell reprogramming in heart failure
Sanford Burnham Prebys Medical Discovery Institute, the La Jolla, California-based nonprofit research institute, has received a USD 1.6 million NIH R01...
Talus Bio backed by NCATS for AI platform to unlock transcription factors as drug targets
Talus Bioscience Inc, a Seattle-based drug discovery company, has received a USD 1.03 million SBIR R44 grant from the National Center for Advancing...
Teva secures ocrelizumab biosimilar rights across US and EU ahead of subcutaneous shift
Teva and Polpharma Biologics strike ocrelizumab biosimilar deal covering US, EU, and key global markets
Forte's becomes first to beat placebo in vitiligo with durable post-treatment gains
Dallas-based Forte Biosciences, Inc. (Nasdaq: FBRX) has reported statistically significant repigmentation data from a Phase Ib double-blind,...
Alchemab backed by British Business Bank with record USD 34 million life sciences bet
UK-based Alchemab Therapeutics has announced a £25 million (USD 34 million) extension to its Series A financing, with the capital provided solely by the...
The AllSci Brief
Systematic R&D and deal news. Daily.